Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

This study has been completed.
Elan Pharmaceuticals
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC Identifier:
First received: June 20, 2012
Last updated: June 12, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2013
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)